

August 4, 2025 | Issue 379

Editor's note

This note is produced by KPMG's Federal Healthcare Advisory Practice and is intended to be short and succinct, less than 360 words, to provide a digestible bite of news relevant to our clients and practices. Links are provided to source material (proposed and final regulations, agency guidance and press releases, reports, research, etc.) when available.



Healthcare regulatory news

CMS <u>released</u> preliminary Medicare Part D bid information for 2026, approving some bids and, for the first time, rejecting standalone prescription drug plan (PDP) bids with substantial premium increases or benefit reductions, while also updating parameters for the voluntary Part D Premium Stabilization Demonstration.

CMS announced a <u>commitment</u> among the Trump Administration and over 60 technology and healthcare companies to create a "patient-centric healthcare ecosystem" focused on interoperability and data sharing between patients and providers. The agency noted that the initiative aims to improve patient care and data management, including enhancements to the CMS Interoperability Framework, development of personalized health tools and apps, and plans to establish a digital health app library on Medicare.gov.

HRSA <u>announced</u> a voluntary 340B Rebate Model Pilot Program to test a new rebate approach for the first 10 drugs selected for Medicare Drug Price Negotiation in 2026. The agency is seeking public comments over a 30-day period to gather input from drug manufacturers and other stakeholders.

HHS <u>announced</u> a \$100M pilot funding opportunity, administered by SAMHSA, to prevent, test for, treat, and cure Hepatitis C (HCV) in individuals with substance use disorder and/or serious mental illness, especially in communities affected by homelessness. The initiative aims to advance care for patients with HCV, improve cure rates, and reduce reinfection.



Healthcare law and policy news

A federal judge temporarily blocked Arkansas's first-in-the-nation law that would prohibit pharmacy benefit managers (PBMs) from owning or operating retail and mail-order pharmacies in the state, ruling the law likely discriminates against out-of-state companies. The law, which had bipartisan support, is now subject to appeal.

The Senate confirmed Susan Monarez, a microbiologist and immunologist, as the new director of the CDC. Prior to her confirmation, Director Monarez served as acting CDC director from January to March 2025, and as deputy director for the Advanced Research Projects Agency for Health (ARPA-H).

During a podcast interview, FDA Commissioner Makary noted that women's healthcare does not receive adequate funding and research, adding that the FDA is considering removing the black box warning labels on certain menopause treatments to reflect updated evidence showing minimal risks.





Questions or comments, please send to us-hclspractice@kpmg.com.











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2025 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. USCS011380-1B

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.